Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

As Moderna plows ahead with its multiyear cost-savings scheme, the mRNA specialist delivered a better second quarter than expected despite sales of its vaccines still leaving something to be ...

Moderna also announced FDA approval for mNEXSPIKE® (mRNA-1283), a next-generation vaccine against COVID-19, for use in all adults aged 65 and older, as well as individuals aged 12-64 years with ...

FDA approved mNEXSPIKE for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor, in late May.

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.99. In the year-ago period, the company h ...

If you want a COVID-19 shot this fall, will your employer’s health insurance plan pay for it? There’s no clear answer.

Rep. Marjorie Taylor Greene, a Peach State Republican and ardent Trump supporter, spoke with Fox News Digital about why she's ...

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...

With so much in flux, it’s important to check with your employer or insurer about coverage policies before you roll up your ...